Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mitchell D. Wilcox who wrote (7990)	5/11/1998 1:42:00 PM
From: OmertaSoldier	Read Replies (1) \| Respond to of 23519

Well we know this so far.. Monday May 11, 1:23 pm Eastern Time Pfizer up as new Viagra Rx hit 269,842 - analyst NEW YORK, May 11 (Reuters) - Shares of Pfizer Inc. (PFE - news) gained Monday amid a broad Wall Street rally and industry data showed continuing growth in new prescriptions of the company's recently launched impotence drug, Viagra. PaineWebber drug analyst Jeff Chaffkin said data from auditing company IMS America showed 269,842 new prescriptions were written for Viagra in the United States during the week ending May 1. The data reflect new prescriptions in the drug's fourth full week of sales, Chaffkin said, reflecting solid growth from the 207,868 new prescriptions written in the prior week. ''They are phenomenal sequential numbers,'' Chaffkin said, referring to the growth from the prior week, adding that week-to-week growth of only 1,000 new prescriptions is more typical of a successful newly launched drug. He predicted sales growth would slow and reach a plateau in coming months, adding that if new weekly prescriptions settled in the 300,000 range that would signfify annual sales of about $1.5 billion for the world's first impotence pill.